Annual General Meeting



idorsia

idorsia

Opening remarks by the Chairman

A start-up like no other

Idorsia has the ideal constellation for bringing successful medicines to patient

>20-year

Heritage of drug discovery

>10

Compounds in the pipeline, with half in late-stage development

>1,300

Highly qualified professionals

Global

Commercial operations in Europe, Japan and the US

Our Strategic Priorities

Our mid-term key priorities to achieve long-term success:

1. Advance late-stage pipeline
2. Successfully launch our new products
3. Bring Idorsia to sustainable profitability
4. Fuel our pipeline with new discoveries
5. Utilize state-of-the-art technologies to drive innovation

Liquidity

in CHF millions, rounding differences may occur





Financial results as of March 31, 2023

Profitability target

The company is committed to reach sustainable profitability in 2025 with global revenue above CHF 1 billion

Based on:

- **Sales of QUVIVIQ**
- **Sales of PIVLAZ in Japan**
- **Tiered royalties on aprocitentan**

Excluding unforeseen events

idorsia

Opening remarks by the Chairman

Business Review

2022 was a transformative year for Idorsia



Our commercial reach



North America

Radnor, Pennsylvania USA
Montreal, Canada

Europe

Allschwil, Switzerland
Paris, France
Munich, Germany
Milan, Italy
Madrid, Spain
Stockholm, Sweden
London, United Kingdom

Asia

Tokyo, Japan
Seoul, South Korea

QUVIVIQ™ (daridorexant)

QUVIVIQ™

daridorexant 25mg, 50mg tablets

Daridorexant is available in the US and the first countries in Europe under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union, in Switzerland and in Canada.

PIVLAZ™ (clazosentan)

PIVLAZ
clazosentan

Clazosentan is only marketed in Japan under the tradename PIVLAZ™. In other countries, clazosentan is investigational, in development and not approved or marketed.

Our drug discovery engine continues to deliver

Compound	Mechanism of action	Target indication	Status
PIVLAZ® (clazosentan)	Endothelin receptor antagonist	Cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage	Commercially available as PIVLAZ in Japan.
QUVIVIQ™ (daridorexant)	Dual orexin receptor antagonist	Insomnia	Commercially available as QUVIVIQ in the US, Germany, and Italy. Approved in the EU, UK, Switzerland and Canada. Filing in Japan expected in H2 2023. Phase 2 in pediatric insomnia – recruiting.
Aprocitentan*	Dual endothelin receptor antagonist	Difficult-to-control (resistant) hypertension	NDA under review in the US, MAA under review in the EU, other filings in preparation
Lucerastat	Glucosylceramide synthase inhibitor	Fabry disease	Phase 3 primary endpoint not met, Open Label Extension study ongoing
Selatogrel	$P2Y_{12}$ inhibitor	Suspected acute myocardial infarction	Phase 3 recruiting
Cenerimod	$S1P_1$ receptor modulator	Systemic lupus erythematosus	Phase 3 recruiting
ACT-1004-1239	ACKR3 / CXCR7 antagonist	Multiple sclerosis and other demyelinating diseases	Phase 2 in preparation
Sinbaglustat	GBA2/GCS inhibitor	Rare lysosomal storage disorders	Phase 1 complete
ACT-1014-6470	C5aR1 antagonist	Immune-mediated disorders	Phase 1
ACT-777991	CXCR3 antagonist	Recent-onset Type 1 diabetes	Phase 1
IDOR-1117-2520	Undisclosed	Immune-mediated disorders	Phase 1

* In collaboration with Janssen Biotech to jointly develop aprocitentan, Janssen Biotech has sole commercialization rights worldwide.

Neurocrine Biosciences has a global license to develop and commercialize ACT-709478 (NBI-827104), Idorsia's novel T-type calcium channel blocker. ACT-709478 was investigated in a Phase 2 study for the treatment of a rare form of pediatric epilepsy. The study did not meet the primary endpoint. ACT-709478 was generally well tolerated. Neurocrine continues to analyze the data generated in the study to determine next steps.

Momentum building catalysts in 2023



†Effective January 15, 2023, QUVIVIQ will be covered at parity to the other branded dual orexin receptor antagonist products for the Express Scripts National Preferred Formulary.

Our achievements in 2022 provide great momentum going into 2023

Be prepared for more